Healthcare Business Rewind: Furiex’ GOOD NEWS, Pfizer TERMINATES Licenses

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Shares of Furiex Pharmaceuticals, Inc. (NASDAQ:FURX) closed higher on the day following confirmation that Takeda Pharmaceutical (TKPYY.PK) has resubmitted New Drug Applications to the FDA for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone, used for treating adult type 2 diabetes. Under its agreement with Takeda, the former may receive a $25 million milestone payment upon the approval of the first of these two NDAs, and additional royalties and sales-based milestones as well.

Don’t Miss: Hospira Second Quarter Earnings Sneak Peek.

Pfizer, Inc. (NYSE:PFE) reports that it is exercising its right to terminate the license and return three development stage products, oxycodone hydrochloride with acetaminophen, hydrocodone bitartrate with acetaminophen and another undisclosed opioid, to Acura Pharmaceuticals, Inc. (NASDAQ:ACUR). A fourth product, that employs Acura’s Aversion Technology, Oxecta Tablets CII, is being commercialized, for which Pfizer will retain all rights and obligations through the current license agreement.

Don’t Miss: Merck Earnings: Expands Margins AGAIN, TOPS Analyst Estimates.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business